| File | |
| language |
eng
|
| Author |
Sakaguchi, Kimiyoshi
Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
Imamura, Toshihiko
Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan Department of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto, Japan
Ishimaru, Sae
Department of Hematology and Oncology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan
Imai,, Chihaya
Department of Pediatrics, Niigata University, Niigata, Japan
Shimonodan, Hidemi
Department of Pediatrics, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan
Fujita, Naoto
Department of Pediatrics, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan
Okada, Keiko
Department of Pediatric Hematology/Oncology, Osaka City General Hospital, Osaka, Japan
Tauchi, Hisamichi
Department of Pediatrics, Ehime University, Toon, Japan
Kato, Motohiro
Division of Stem Cell Transplant and Cellular Therapy, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan
Kojima, Yasuko
Department of Pediatrics, Toho University Omori Medical Center, Tokyo, Japan
Watanabe, Arata
Department of Pediatrics, Nakadori General Hospital, Akita, Japan
Deguchi, Takao
Department of Pediatrics, Mie University, Tsu, Japan
Hashii, Yoshiko
Department of Pediatrics, Osaka University, Suita, Japan
Kiyokawa, Nobutaka
Department of Pediatric Hematology and Oncology Research, Research Institute, National Center for Child Health and Development, Tokyo, Japan
Taki, Tomohiko
Department of Medical Technology, Kyorin University Faculty of Health Sciences, Mitaka, Japan
Saito Akiko M.
Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
Horibe, Keizo
Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
Manabe, Atsushi
Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Sato, Atsushi
Department of Hematology/Oncology, Miyagi Children's Hospital, Sendai, Japan
Koh, Katsuyoshi
Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan
|
| Description | Background
Rearrangements of chromosome 8q24/MYC (8q24/MYC-r), resulting from t(8;14)(q24;q32), t(2;8)(p11;q24), or t(8;22)(q24;q11), are mainly associated with Burkitt lymphoma/leukemia (BL) and rarely observed in patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL). The characteristics of BCP-ALL with 8q24/MYC-r are poorly understood. Procedure A retrospective nationwide study of data from patients with pediatric BCP-ALL with 8q24/MYC-r in Japan was conducted to clarify the clinical and biological characteristics associated with 8q24/MYC-r BCP-ALL. Results Ten patients with BCP-ALL with 8q24/MYC-r, including three with double-hit leukemia (DHL) (two with t(8;14)(q24;q32) and t(14;18)(q32;q21) and one with t(8;14) and t(3;22)(q27;q11)), were identified. Patients with BCP-ALL with 8q24/MYC-r had higher median age and uric acid and lactate dehydrogenase levels, than those without 8q24/MYC-r. All patients were initially treated with ALL-type chemotherapy; however, four, including one with DHL, were switched to BL-type chemotherapy, based on cytogenetic findings. One patient relapsed after standard-risk ALL-type chemotherapy, and two patients with DHL did not attain complete remission with chemotherapy; all three died within 11 months. The other seven patients treated with BL-type or high-risk ALL-type chemotherapy are alive without disease. Conclusions The clinical and laboratory features of BL with IG-MYC rearrangement, displaying a BCP immunophenotype (Wagener et al. and Herbrueggen et al. termed it as pre-BLL), are similar to those of BCP-ALL with 8q24/MYC-r. Low-risk ALL-type chemotherapy may not be appropriate for them, and further studies are required to establish an adequate therapeutic strategy. Further studies of DHL to identify new treatment strategies are also needed. |
| Journal Title |
Pediatric blood & cancer
|
| Volume | 67
|
| Issue | 7
|
| ISSN | 1545-5009
|
| ISSN（Online） | 1545-5017
|
| Published Date | 2020-04-23
|
| DOI | |
| PubMed ID | |
| Publisher | Hoboken, N.J. : John Wiley, c 2004-
|
| NII Type |
Journal Article
|
| Format |
PDF
|
| Text Version |
著者版
|
| Gyoseki ID | 39958
|
| OAI-PMH Set |
Faculty of Medicine
|
